CLAVINDL-CV 625: A New Formulation for Broad-Spectrum Bacterial Infection Management
Bacterial infections can affect different parts of the body, including the respiratory tract, ear, nose and throat, urinary system, skin and soft tissues, and dental areas. Effective management of bacterial infections often requires an appropriate antibiotic selected by a qualified healthcare professional.
Introducing CLAVINDL-CV 625 Tablets, a new formulation from Lekindle Drugs, containing Amoxicillin & Potassium Clavulanate Tablets IP. This combination brings together amoxicillin with clavulanic acid to provide broad antibacterial coverage against susceptible bacterial infections.
With its combination-based formulation, CLAVINDL-CV 625 is designed to support healthcare professionals in managing a range of commonly encountered bacterial infections.
What is CLAVINDL-CV 625?
CLAVINDL-CV 625 Tablets contain a combination of Amoxicillin and Potassium Clavulanate. Amoxicillin belongs to the penicillin group of antibiotics, while clavulanic acid helps overcome resistance caused by certain beta-lactamase enzymes produced by bacteria.
This combination allows the antibiotic to remain effective against certain bacteria that may otherwise reduce the activity of amoxicillin.
The formulation is available in 625 mg tablets, with the product pack shown as 10 × 10 Tablets, manufactured and marketed by Lekindle Drugs.
How Does the Amoxicillin-Clavulanate Combination Work?
Amoxicillin works by interfering with bacterial cell-wall formation, which helps inhibit the growth of susceptible bacteria.
Some bacteria, however, can produce enzymes known as beta-lactamases that can break down certain antibiotics. Clavulanic acid helps inhibit many of these enzymes, allowing amoxicillin to work against a broader range of susceptible bacteria.
Therefore, the combination of amoxicillin and clavulanic acid can provide broader antibacterial activity than amoxicillin alone in appropriate clinical situations.
Uses of CLAVINDL-CV 625
CLAVINDL-CV 625 may be prescribed by healthcare professionals for susceptible bacterial infections affecting different parts of the body.
1. Respiratory Tract Infections
The formulation may be used in the management of certain bacterial respiratory tract infections. Depending on the clinical condition, it may be prescribed for infections such as bacterial sinusitis, bronchitis and pneumonia.
The choice of antibiotic should always depend on the patient’s condition and the healthcare professional’s assessment.
2. Ear, Nose & Throat Infections
Bacterial infections involving the ear, nose and throat may require antibiotic treatment. Amoxicillin and clavulanic acid combinations are commonly used in appropriate cases of conditions such as otitis media, tonsillitis and pharyngitis.
CLAVINDL-CV 625 provides a combination approach for healthcare professionals when bacterial infection is suspected or confirmed.
3. Urinary Tract Infections
Urinary tract infections can involve the bladder, kidneys or other parts of the urinary system. When the causative bacteria are susceptible, an amoxicillin-clavulanate combination may be considered by a healthcare professional.
Antibiotic selection should ideally be based on the infection, local resistance patterns and, where appropriate, laboratory testing.
4. Skin & Soft Tissue Infections
Bacterial infections can also affect the skin and underlying soft tissues. Conditions such as certain wound infections and cellulitis may require antibiotic treatment.
CLAVINDL-CV 625 can be considered for susceptible bacterial infections when prescribed by a qualified healthcare professional.
5. Dental Infections
Dental infections can sometimes involve bacterial infection around teeth and surrounding tissues. Depending on the diagnosis, an amoxicillin-clavulanate combination may be prescribed for certain dental infections and oral bacterial infections.
Patients should consult a dentist or doctor rather than taking antibiotics without professional advice.
Key Features of CLAVINDL-CV 625
The new formulation from Lekindle Drugs combines two complementary components—amoxicillin and clavulanic acid—to provide broad antibacterial coverage where clinically appropriate.
Key highlights include:
- Amoxicillin and Potassium Clavulanate combination
- 625 mg tablet formulation
- Broad-spectrum antibacterial activity against susceptible organisms
- Suitable for various bacterial infection categories when prescribed
- Useful across respiratory, ENT, urinary, skin and dental indications
- Manufactured by Lekindle Drugs
Why Choose a Combination Formulation?
Bacterial resistance can make the treatment of some infections more challenging. Certain bacteria produce beta-lactamase enzymes that can reduce the effectiveness of some beta-lactam antibiotics.
The addition of clavulanic acid helps inhibit many of these enzymes and can extend the antibacterial activity of amoxicillin against susceptible beta-lactamase-producing bacteria.
However, antibiotics should never be selected simply because they offer broader coverage. The appropriate medicine, dose and duration should be determined by a qualified healthcare professional according to the patient’s diagnosis.
Safety and Responsible Antibiotic Use
CLAVINDL-CV 625 is a prescription medicine and should be taken only on the advice of a qualified doctor or healthcare professional. The prescribed dose and duration should be followed carefully.
Patients should not stop an antibiotic early, share their medicine with another person, or use leftover antibiotics for a new illness. Common adverse effects of amoxicillin-clavulanate may include gastrointestinal symptoms such as nausea, vomiting or diarrhea, while allergic reactions can occur in susceptible individuals.
Anyone with a known allergy to penicillin or related antibiotics should inform their doctor before treatment.
Lekindle Drugs – Committed to Quality Healthcare
With the introduction of CLAVINDL-CV 625, Lekindle Drugs continues to expand its pharmaceutical portfolio with combination formulations designed for healthcare needs.
The Amoxicillin and Potassium Clavulanate combination represents an established approach to managing susceptible bacterial infections across multiple therapeutic areas. CLAVINDL-CV 625 offers healthcare professionals a convenient 625 mg tablet formulation for appropriate clinical use.
For product information, availability and professional enquiries regarding CLAVINDL-CV 625, contact Lekindle Drugs.
